DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Toviaz (Fesoterodine Fumarate) - Published Studies

 
 



Toviaz Related Published Studies

Well-designed clinical trials related to Toviaz (Fesoterodine)

Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. [2011.11]

Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. [2011.05]

Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. [2011.05]

Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. [2011.05]

Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. [2010.09.21]

Thorough QT study of the effect of fesoterodine on cardiac repolarization. [2010.05]

Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. [2010.05]

Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. [2010.05]

Efficacy of fesoterodine over 24 hours in subjects with overactive bladder. [2010.04]

Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. [2010.04]

The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. [2010.02]

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. [2010.01]

Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. [2010.01]

Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. [2010]

Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? [2010]

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. [2010]

Efficacy of fesoterodine over 24 hours in subjects with overactive bladder. [2010]

Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. [2010]

Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. [2010]

Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. [2009.09]

Efficacy and tolerability of fesoterodine in women with overactive bladder. [2009.07]

Influence of food on the pharmacokinetic profile of fesoterodine. [2009.06]

The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. [2009.03.07]

Pharmacokinetic profile of fesoterodine. [2008.11]

Comparison of fesoterodine and tolterodine in patients with overactive bladder. [2008.11]

Impact of fesoterodine on quality of life: pooled data from two randomized trials. [2008.07]

Fesoterodine dose response in subjects with overactive bladder syndrome. [2008.05]

Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. [2007.12]

Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. [2007.10]

Well-designed clinical trials possibly related to Toviaz (Fesoterodine)

Which anticholinergic drug for overactive bladder symptoms in adults. [2012]

Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? [2011.07]

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model. [2011.05.20]

Other research related to Toviaz (Fesoterodine)

Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. [2014]

Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometry. [2014]

Evaluation of fesoterodine fumarate for the treatment of an overactive bladder. [2013]

Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies. [2011.11.30]

Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving alpha-blocker treatment for lower urinary tract symptoms. [2011.10.03]

Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. [2011.08]

Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine. [2011.03]

Early onset of fesoterodine efficacy in subjects with overactive bladder. [2011.02]

Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study. [2011.02]

Review of fesoterodine. [2011]

Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. [2010.12]

Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? [2010.09]

Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder. [2010.08.19]

Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction. [2010.08]

The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. [2010.08]

Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. [2010.07]

Fesoterodine fumarate. [2010.02]

Thorough QT study of the effect of fesoterodine on cardiac repolarization. [2010]

Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. [2010]

The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. [2010]

Fesoterodine for the treatment of overactive bladder. [2009.12]

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. [2009.04]

Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. [2009.04]

Fesoterodine: a new agent for treating overactive bladder. [2009.03]

Darunavir: a review of its use in the management of HIV infection in adults. [2009]

Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. [2008.07]

Other possibly related research studies

Overactive Bladder Drugs and Constipation: A Meta-Analysis of Randomized, Placebo-Controlled Trials. [2010.07.02]

Tolterodine extended-release for overactive bladder. [2009.09]

[Anticholinergic treatment of overactive bladder syndrome. Is it all the same?] [2009.03]

Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? [2009.01]

Gateways to clinical trials. [2008.06]

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. [2008.09]

Gateways to clinical trials. [2007.11]

Update on the treatment of overactive bladder. [2011.07]

Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. [2011.02.23]

Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. [2011.04]

Gateways to clinical trials. [2010.07]

Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. [2011.01]

Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. [2012]

Long-term efficacy and safety of questionnaire-based initiation of urgency urinary incontinence treatment. [2013]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017